Conexiant’s news site is now MDSpire News. Learn more
Advertisement
HBV vaccine policy shift may raise infections
A modeling study projects 83% more childhood chronic hepatitis B infections and 1.8 million susceptible young adults under a shared decision-making vaccination strategy.
To estimate how replacing universal hepatitis B vaccination at birth with delayed vaccination or shared clinical decision-making could affect childhood HBV infections and susceptibility.
Approach:
Model: Investigators used a Markov cohort model to simulate 3.6 million US-born infants through age 20 years.
Strategies: The model compared universal birth-dose vaccination, universal vaccination beginning at age 2 months, and vaccination through shared clinical decision-making.
Analyses: Scenario and sensitivity analyses examined vaccine uptake, maternal HBV prevalence, childhood exposure risks, and later vaccine initiation.
Key Findings:
Projected chronic infections by age 20 were 255 with universal birth-dose vaccination, 303 with vaccination deferred to 2 months (19% higher), and 467 with shared decision-making (83% higher).
Projected numbers susceptible at age 20 were approximately 232,000, 474,000, and 1.8 million, respectively; under shared decision-making, about half the cohort remained susceptible.
With lower vaccine uptake, projected chronic infections rose to 357 under deferred vaccination and 575 under shared decision-making.
In a higher-risk scenario, projected infections were 1,700 with deferred vaccination and 2,192 with shared decision-making, compared with 255 under the base-case birth-dose strategy.
Across 1,000 probabilistic sensitivity simulations, universal birth-dose vaccination consistently produced fewer projected chronic infections than the alternatives.
Interpretation:
The model projected more childhood chronic HBV infections and greater susceptibility by age 20 when universal vaccination at birth was replaced by delayed vaccination or shared clinical decision-making.
Limitations:
Household and community transmission risks were uncertain, and the model did not distinguish risks by setting.
The model did not account for partial immunity after incomplete vaccination, subsequent liver disease, mortality, onward transmission, or economic consequences.
Projections assuming broad implementation of federal policy changes may not apply where state health departments or medical societies continue to recommend universal birth-dose vaccination.
Conclusion:
The authors noted that even a small number of additional childhood infections could have substantial clinical, public health, and economic effects.
U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.